Clinical Research Directory

Inclusion Criteria: * 16 individuals living with T1D and abdominal obesity, as defined by the International Diabetes Federation country/ethnic group-specific criteria (https://www.idf.org/e-library/consensus-statements/60- \[1\]. Treatment for T1D will be intensive insulin therapy on continuous pump perfusion with continuous glucose monitoring. * 16 individuals with normoglycemia (i.e., HbA1c below 6.0%) matched for sex, age (± 5 years), waist circumference (± 3 cm), and menopausal status. Exclusion Criteria: * less than 70% of time in glycemic range (for T1D); * history of primary dyslipidemia (LDL-cholesterol over 5 mmol/L or TG over 10 mmol/L) or uncontrolled high blood pressure (over 160/100 mmHg) precluding the withdrawal of lipid lowering and anti-hypertensive agents as per protocol; * presence of overt cardiovascular, liver or renal disease (except microalbuminuria without reduced kidney function), or other uncontrolled medical conditions; * use of any medication other than insulin that may affect lipid or carbohydrate metabolism and that cannot be stopped prior to testing; * current or planned pregnancy within the next 6 months; * any contraindication to MRI. * Being allergic to eggs * Smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day * Having participated to a research study with exposure to radiation in the last year before the start of the study